Scotiabank analyst George Farmer maintains $Syndax Pharmaceuticals (SNDX.US)$ with a hold rating, and maintains the target price at $18.
According to TipRanks data, the analyst has a success rate of 48.8% and a total average return of 9.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Syndax Pharmaceuticals (SNDX.US)$'s main analysts recently are as follows:
The FDA's approval of Revuforj has dissipated prior concerns surrounding the three-month extension. The implementation of a boxed warning for differentiation syndrome on Revuforj is anticipated to be consistent across the broader menin-inhibitor class, thus not posing a competitive disadvantage.
The approval of REVUFORJ, revumenib, for relapsed or refractory acute leukemia with KMT2A translocation in adults and pediatric patients was granted by the FDA six weeks prior to the anticipated PDUFA date. The safety and efficacy indications are largely in line with expectations. Additionally, the recommendation for initial QTc monitoring with treatment is viewed as not being burdensome.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
丰业银行分析师George Farmer维持$Syndax Pharmaceuticals (SNDX.US)$持有评级，维持目标价18美元。
根据TipRanks数据显示，该分析师近一年总胜率为48.8%，总平均回报率为9.9%。
此外，综合报道，$Syndax Pharmaceuticals (SNDX.US)$近期主要分析师观点如下：
美国食品和药物管理局对Revuforj的批准消除了先前对延期三个月的担忧。预计在Revuforj上实施的分化综合征方框警告将在更广泛的男性抑制剂类别中保持一致，因此不会构成竞争劣势。
美国食品药品管理局在预期的PDUFA日期前六周批准了REVUFORJ，即revumenib，用于成人和儿科患者复发或难治性急性白血病，并伴有 KMT2A 易位。安全性和有效性适应症基本符合预期。此外，建议通过治疗进行初步的QtC监测被认为并不繁重。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
